Clinical and pathological study of feline mammary fibroadenomatous change associated with depot medroxyprogesterone acetate therapy
نویسندگان
چکیده
منابع مشابه
Depot Medroxyprogesterone Acetate and Bone Density
The 2002 National Survey of Family Growth reported that 5.3% of all US women aged 15 through 44 currently using contraception used DMPA.1 Among contraceptors, 13.9% of those aged 15 to 19 and 10.1% of those aged 20 to 24 currently used DMPA compared with 1.6% of those aged 40 to 44.1 Decreasing rates of adolescent pregnancy between 1995 and 2002 are considered to be due in part to increased use...
متن کاملMedroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial☆☆☆
OBJECTIVE To describe medroxyprogesterone acetate (MPA) levels among Kenyan depot medroxyprogesterone acetate (DMPA) users in the FEM-PrEP HIV prevention trial, and to compare MPA levels between ARV for HIV prevention (treatment) and placebo groups. STUDY DESIGN We measured MPA in previously collected plasma samples from 63 Kenyan trial participants who used DMPA for one or two complete inter...
متن کاملGenital Injury Signatures and Microbiome Alterations Associated With Depot Medroxyprogesterone Acetate Usage and Intravaginal Drying Practices
Background Increasing evidence suggests depot medroxyprogesterone acetate (DMPA) and intravaginal practices may be associated with human immunodeficiency virus (HIV-1) infection risk; however, the mechanisms are not fully understood. This study evaluated the effect of DMPA and intravaginal practices on the genital proteome and microbiome to gain mechanistic insights. Methods Cervicovaginal se...
متن کاملUse of depot medroxyprogesterone acetate and fracture risk.
CONTEXT Depot medroxyprogesterone acetate (DMPA), which has a high rate of use among teenagers in Europe and the United States, has been associated with impaired bone mineral acquisition during adolescence and accelerated bone loss in later life. Studies on the association between DMPA use and fracture risk are limited. OBJECTIVE We aimed at evaluating the relationship between use of hormonal...
متن کاملBone loss associated with long-term use of depot medroxyprogesterone acetate.
On 17 November 2004, the United States Food and Drug Administration issued a black box warning on the long-term use of depot medroxyprogesterone acetate stating that bone loss might be irreversible with use of more than 2 years. Despite the seriousness of such a safety warning, the Food and Drug Administration provided no clinical recommendations. Various professional bodies have made different...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arquivo Brasileiro de Medicina Veterinária e Zootecnia
سال: 2004
ISSN: 0102-0935
DOI: 10.1590/s0102-09352004000200020